Fatal unintentional poisonings from pharmaceutical opioids have increased more than three-fold in the last decade, reaching epidemic proportions. Naloxone is an effective, Food and Drug Administration approved opioid antidote usually administered by first responders in emergency settings to reverse respiratory depression due to opioid poisoning. Community-based harm reduction organizations have developed effective overdose education and naloxone distribution programs for heroin and illicit pharmaceutical opioid users in a number of states. Widespread prescribing of naloxone for take-home use to patients on prescription opioids may prevent overdose deaths through earlier treatment. Primary care settings in large health care systems, offer the opportunity to reach many individuals at risk for opioid overdose, particularly individuals on high dose opioids. In the primary care setting, patients at risk can be identified and can be counseled on overdose risk, improving communication between clinicians and patients about the risks of opioids. Primary care providers can also prescribe naloxone. In this study we will examine the key barriers and facilitators to prescribing naloxone for take-home use and develop and pilot test an overdose risk assessment, counseling and naloxone prescription intervention for delivery in primary care settings. This study will develop a feasible, information-technology supported overdose prevention intervention for use in large health care systems. We will obtain key preliminary data to support a future large scale, multi-site randomized controlled trial of this intervention from patients and providers in three distinct health systems: an academic medical center, a managed care organization, and a safety net hospital system. The intervention will be targeted to medical clinicians who care for high-risk chronic prescription opioid users in primary care, including general medical and HIV clinics.
Our Specific Aims are to: (1) Assess the knowledge, attitudes and beliefs about overdose prevention and naloxone prescription among patients, clinicians, pharmacists and clinical administrators in three health care systems. Through interviews and focus groups, we will determine the barriers and facilitators to overdose risk assessment, counseling and naloxone prescription for take-home use. (2) Develop an efficient overdose risk assessment, counseling and naloxone prescription intervention for delivery in diverse primary care practices. (3) Pilot test a randomized controlled trial of a naloxone prescription interventio that includes overdose risk assessment and counseling and determine its effects on the number of naloxone prescriptions delivered to patients This mixed methods study is responsive to federal calls for studies on widening access to naloxone and NIDA's interest in interventions to prevent drug-related injuries. Together, these aims will lead to the development of a novel intervention which has the potential to reduce fatalities from pharmaceutical opioid overdoses.

Public Health Relevance

Rates of fatal overdoses from pharmaceutical opioids have been rising at unprecedented rates. Naloxone is a medication which can reverse opioid overdose. In this study, we will develop and pilot test an intervention to enhance overdose risk assessment, counseling and naloxone prescription in diverse primary care settings. This intervention has the potential to reduce overdose deaths by expanding access to a life-saving medication among a large number of patients at risk.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Planning Grant (R34)
Project #
Application #
Study Section
Risk, Prevention and Intervention for Addictions Study Section (RPIA)
Program Officer
Duffy, Sarah Q
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Mueller, Shane R; Koester, Stephen; Glanz, Jason M et al. (2017) Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain. J Gen Intern Med 32:277-283
Davis, Corey S; Burris, Scott; Beletsky, Leo et al. (2016) Co-prescribing naloxone does not increase liability risk. Subst Abus 37:498-500
Frank, Joseph W; Levy, Cari; Calcaterra, Susan L et al. (2016) Naloxone Administration in US Emergency Departments, 2000-2011. J Med Toxicol 12:148-56
Frank, Joseph W; Levy, Cari; Matlock, Daniel D et al. (2016) Patients' Perspectives on Tapering of Chronic Opioid Therapy: A Qualitative Study. Pain Med 17:1838-1847
Metz, Torri D; Rovner, Polina; Hoffman, M Camille et al. (2016) Maternal Deaths From Suicide and Overdose in Colorado, 2004-2012. Obstet Gynecol 128:1233-1240
Bartels, Karsten; Binswanger, Ingrid A; Hopfer, Christian J (2016) Sources of Prescription Opioids for Nonmedical Use. J Addict Med 10:134
Bartels, Karsten; Mayes, Lena M; Dingmann, Colleen et al. (2016) Opioid Use and Storage Patterns by Patients after Hospital Discharge following Surgery. PLoS One 11:e0147972
Calcaterra, Susan L; Drabkin, Anne D; Leslie, Sarah E et al. (2016) The hospitalist perspective on opioid prescribing: A qualitative analysis. J Hosp Med 11:536-42
Calcaterra, Susan L; Keniston, Angela; Blum, Joshua et al. (2015) The Association Between Stimulant, Opioid, and Multiple Drug Use on Behavioral Health Care Utilization in a Safety-Net Health System. Subst Abus 36:407-12
Binswanger, Ingrid A; Koester, Stephen; Mueller, Shane R et al. (2015) Overdose Education and Naloxone for Patients Prescribed Opioids in Primary Care: A Qualitative Study of Primary Care Staff. J Gen Intern Med 30:1837-44

Showing the most recent 10 out of 14 publications